Resumen

AVENDANO-ALVARADO, Gerardo. Virus B and interferon. Acta méd. costarric [online]. 2008, vol.50, suppl.3, pp.45-48. ISSN 0001-6002.

The appearance of new drugs and new forms of diagnosing has transformed chronic hepatitis B from being a lethal disease to becoming a treatable and even curable disease. There are two kinds of chronic hepatitis B, one that develops with antigen e positive and the other one with antigen e negative. This chronic disease can appear with normal ALT, ALT continuous elevation, and ALT fluctuations without becoming normal or intermittent elevations. The success of the antiviral therapy for HBVincludes, suppressing the replicative state to the lowest level possible, getting biochemical and histological amelioration; and preventing the development of complications. There are two strategies for HBV treatment, one with limited duration (interferon) and the other long term treatment (nucleotide analogue). There are factors that influence satisfactorily, the response to the treatment with interferon: low levels of HBV DNA, high levels of ALT, long levels of HBeAg and A & B genotypes. Alpha interferon and more recently Pegylated α-2a have been used for the management of HBVe (+) and HBVe (-). The Pegylated interferon has shown to be more effective than conventional interferon, in terms of ALT normalization, HBe loss, and sustainable loss of HBV DNA. The Pegylated interferon has also shown to be superior to the combined therapy or only to lamivudine, in terms of range response and seroconversion in e (+) and e (-). There is still controversy when treating patients with e (-) who need long term usage of interferon or those who need to start nucleoside analogue.

Palabras clave : treatment; hepatitis B virus; pegylated interferon.

        · resumen en Español     · texto en Español     · Español ( pdf )